Simulations Plus Stock

Simulations Plus EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Simulations Plus (SLP) as of Jul 24, 2026 is 11.88. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 17.07 — a change of -30.42% (lower).

EV/OCF

11.88

YoY

-30.42%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Simulations Plus is 2026 11.88 . EV/OCF (Enterprise Value to Operating Cash Flow) of Simulations Plus was 2025 17.07 . It decreases by -30.42% lower compared to the previous year.
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Simulations Plus is 11.88 in 2026.

Access this data via the Eulerpool API

Valuation — Simulations Plus

All Key Metrics — Simulations Plus